<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748304</url>
  </required_header>
  <id_info>
    <org_study_id>Huashan 003</org_study_id>
    <nct_id>NCT02748304</nct_id>
  </id_info>
  <brief_title>Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to observe the effect of sorafenib combined with aspirin in
      preventing the recurrence in high-risk patients with hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recurrence of hepatocellular carcinoma(HCC）is the main problem during the treatment.
      Although some methods such as interferon may be effective in preventing the recurrence, there
      is still no clear effective approach widely accepted for everyone.

      Sorafenib, a kind of tyrosine kinase inhibitor, which inhibiting proliferation and inducing
      apoptosis of tumor cell by inhibiting the raf/MEK/ERK pathway, and anti-angiogenesis by
      targeting Vascular Endothelial Growth Factor Receptor(VEGFR), has now become the standard
      treatment of advanced HCC patients. Although the STORM studies have shown that adjuvant
      sorafenib for such patients did not significantly affect recurrence-free survival, time to
      recurrence, or overall survival. The patients recruiting in the study were mostly early
      stage, for middle and late stage patients, whether sorafenib can reduce tumor recurrence
      after surgical resection and prolong survival remains to be further study.

      Aspirin is a kind of nonsteroidal anti-inflammatory drugs. It is the first hint of aspirin's
      potential role in tumor prevention and treatment when Gasic found that tumor metastasis is
      reduced in thrombocytopenia mice, and then the research confirmed that aspirin treatment can
      significantly reduce the tumor metastasis. In recent years, a lot of epidemiological evidence
      and clinical trials found that aspirin played an important role in cancer prevention, at the
      same time, more experimental study has found that it can also play a role in tumor treatment.
      Our previous animal experiments found that a combination of sorafenib and aspirin can reverse
      the negative effect of sorafenib which promoted tumor metastasis, and obviously prolong
      survival of a tumor-burdened nude mice.

      So, the study is to observe the effect of sorafenib combined with aspirin in preventing the
      recurrence in high-risk patients with hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related bleedings who use aspirin</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>just follow up after liver resection in HCC patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use sorafenib after liver resection in HCC patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib and aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use sorafenib and aspirin after liver resection in HCC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>just follow up</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>sorafenib 400mg bid po</description>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_label>sorafenib and aspirin</arm_group_label>
    <other_name>sorafenib treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin 100mg qd po</description>
    <arm_group_label>sorafenib and aspirin</arm_group_label>
    <other_name>aspirin treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The characteristics of the treatment history:

               1. No sorafenib treatment history, no sorafenib allergies.

               2. No chemotherapy, radiotherapy and transcatheter arterial chemoembolization(TACE)
                  treatment history before surgery.

          -  The characteristics of the tumor:

               1. The pathological results is hepatocellular carcinoma.

               2. Meet any of the following articles:

                    -  Pathological prompt microvascular invasion(MVI) class II, and incorporate
                       any of the following:Tumor number&gt;3,Tumor size&gt;8cm,Tumor margin is not clear
                       and no complete capsule.

                    -  With the embolus in Portal vein, hepatic vein or bile duct.

                    -  Preoperative rupture or invasion the adjacent organs.

                    -  The positive cut edge.

                    -  Residual lesions showed by Postoperative digital subtraction
                       angiography(DSA).

                    -  Alpha fetoprotein(AFP) did not drop to normal range two months after
                       surgery.

          -  The characteristics of the patients:

               1. The patient age was between 18-75.

               2. The American Society of Anesthesiologists(ASA）score was I-III.

               3. No history of esophageal varices and gastrointestinal bleeding.

               4. The Child-pugh score was A.

               5. Routine blood test: the leukocyte&gt;2.5*10^9, platelet&gt; 60*10^9.

               6. The Prothrombin time was prolonged less than 2 second.

               7. The Eastern Cooperative Oncology Group(ECOG) score was less than 2 points

        Exclusion Criteria:

          -  Sorafenib treatment before surgery.

          -  Pregnant or lactating women.

          -  The Child-pugh score was B-C.

          -  Patients with other malignant tumor.

          -  Patients with mental illness.

          -  Patients participated in other clinical trials in last three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lunxiu Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of general surgery, Huashan hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Lu, MD</last_name>
    <phone>862152887175</phone>
    <email>lulu@huashan.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Lu, MD</last_name>
      <phone>862152887175</phone>
      <email>lulu@huashan.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907-17. Review.</citation>
    <PMID>14667750</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006 Jul;132(7):458-65. Epub 2006 Mar 24.</citation>
    <PMID>16557381</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.</citation>
    <PMID>18477802</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </results_reference>
  <results_reference>
    <citation>De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L, Campani D, Bartolozzi C, Lencioni R, Filipponi F. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014 Jan-Feb;46(1):241-4. doi: 10.1016/j.transproceed.2013.10.035.</citation>
    <PMID>24507059</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.</citation>
    <PMID>26361969</PMID>
  </results_reference>
  <results_reference>
    <citation>Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968 Sep;61(1):46-52.</citation>
    <PMID>5246932</PMID>
  </results_reference>
  <results_reference>
    <citation>Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet. 1972 Oct 28;2(7783):932-3.</citation>
    <PMID>4116642</PMID>
  </results_reference>
  <results_reference>
    <citation>Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50. doi: 10.1016/S0140-6736(10)61543-7. Epub 2010 Oct 21.</citation>
    <PMID>20970847</PMID>
  </results_reference>
  <results_reference>
    <citation>Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011 Jan 1;377(9759):31-41. doi: 10.1016/S0140-6736(10)62110-1. Epub 2010 Dec 6.</citation>
    <PMID>21144578</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahdi JG, Alkarrawi MA, Mahdi AJ, Bowen ID, Humam D. Calcium salicylate-mediated apoptosis in human HT-1080 fibrosarcoma cells. Cell Prolif. 2006 Aug;39(4):249-60.</citation>
    <PMID>16872361</PMID>
  </results_reference>
  <results_reference>
    <citation>Saad-Hossne R, Prado RG, Hossne WS. Effects of acetylsalicylic acid and acetic acid solutions on VX2 liver carcinoma in rabbits. In vivo analysis. Acta Cir Bras. 2007 Jul-Aug;22(4):299-308.</citation>
    <PMID>17625669</PMID>
  </results_reference>
  <results_reference>
    <citation>Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 2002 May;35(5):1117-24.</citation>
    <PMID>11981761</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology. 2012 Dec;143(6):1641-1649.e5. doi: 10.1053/j.gastro.2012.08.032. Epub 2012 Aug 23.</citation>
    <PMID>22922424</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One. 2013 May 31;8(5):e65023. doi: 10.1371/journal.pone.0065023. Print 2013.</citation>
    <PMID>23741443</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>October 9, 2016</last_update_submitted>
  <last_update_submitted_qc>October 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Lunxiu Qin</investigator_full_name>
    <investigator_title>Director of the general surgery department, Huashan hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

